For reps
A mobile-first daily workspace for agenda, HCP context, call planning, compliant visit reporting, missed-call reasons, and offline-ready capture.
Daloy by RagingRiver ICT
Daloy helps medical representatives, managers, and commercial operations teams plan visits, capture compliant field activity, manage HCP workflows, and turn real-time signals into better execution decisions.
Working Thesis
Daloy should be a simpler, real-time system for medical representatives, field managers, and commercial operations teams. It should not begin as a generic CRM.
The product should serve pharma teams that need fast call reporting, compliant customer updates, lightweight approvals, and real-time coaching signals without the burden of a large enterprise CRM implementation.
What is Daloy?
A mobile-first daily workspace for agenda, HCP context, call planning, compliant visit reporting, missed-call reasons, and offline-ready capture.
Live visibility into activity, coverage gaps, approvals, exceptions, and coaching opportunities while the cycle is still active.
Governed HCP master-data changes, configurable business rules, audit trails, imports/exports, and practical dashboards for SFE teams.
Core promise
In pharma field work, a visit report is not just a note that a representative saw a doctor. It should be a structured, policy-aware activity record that captures what happened in the visit while respecting company rules, promotional boundaries, privacy requirements, and audit expectations.
Daloy should guide reps to record the required facts quickly — who was visited, when, where, what products or topics were discussed, what next action was agreed, and why a planned call was missed or changed — without encouraging free-form claims that could create compliance risk.
Strategic Framing
RagingRiver’s opportunity is not to present itself as a generic AI vendor. Most local pharma companies can benefit from AI capabilities, but many do not have the internal expertise to identify practical AI use cases, prepare the required data foundation, and govern AI safely in regulated commercial workflows. At the same time, many AI experts do not carry the pharma IT and SFE operating experience needed to understand field execution realities.
Daloy should therefore combine the July 2 product plan with RagingRiver’s deeper positioning: AI for pharma, grounded in decades of pharma field-system experience. iDoXs served as an SFE backbone or nerve system — a way for decision-makers to communicate strategy to the field and measure results back. Daloy keeps that strategy-to-field value proposition, then adds intelligence.
Strategic idea
RagingRiver can help Philippine pharma companies adopt AI in ways that are practical, workflow-aware, and commercially useful.
Daloy builds from RagingRiver’s DocCS/iDoXs experience, including SFE workflows, HCP engagement, field reporting, manager visibility, and commercial operations.
The platform should not only record activity. It should guide the field, surface risks, explain gaps, and help leaders adjust strategy before the cycle is lost.
Starting Assumptions
Previous pharma viability work suggested there is enough opportunity to continue, but it is not yet a validated product bet.
Legacy iDoXs assets point to fewer steps, one-place workflows, minimal backend processing, real-time updates, and manager collaboration.
A regional or mid-market pharma company, distributor, or outsourced sales organization with spreadsheet-heavy, delayed, or overbuilt SFE processes.
The MVP should be designed for regulated commercial activity from day one, while avoiding patient-level data unless specifically required.
Product Positioning
One-liner
MVP Scope
HCP Co-pilot Governance
Compliance and Trust Requirements
Differentiation
Faster to deploy than enterprise CRM.
Easier for representatives to use every day.
Built around live manager collaboration, not end-of-month reporting.
Regional pharma configuration without becoming operationally heavy.
Avoid competing head-on with large CRM suites on breadth. Daloy should win as a focused field execution and manager visibility layer.
Validation Plan
Target: 10–15 interviews.
Exit criteria: 3 buyer-side stakeholders confirm active, budget-relevant pain; 2 organizations agree to review a clickable prototype or pilot proposal; first-market scope is selected.
Clickable prototype should show daily agenda, call planning, HCP profile, HCP co-pilot management, report visit flow, HCP inclusion request, manager live feed, approval queue, and KPI dashboard.
Exit criteria: reps complete the core visit flow in under 60 seconds; managers identify at least 3 actionable live-feed events; operations confirms the admin model fits their sales model.
Pilot shape: 1 company, 1–2 teams, 10–30 representatives, 2–4 managers, 8–12 weeks.
Build Roadmap
Technical Direction
Pricing Hypotheses
Pricing should be tested during discovery rather than locked now.
Internal Build Workspace
Daloy should be built through an AI-assisted software development life cycle, but not as uncontrolled automation. The portal should guide the team through each facet of development, capture decisions, generate artifacts, and keep human ownership clear.
The practical goal is a working cockpit: Boss Rio and the team can ask AI for help in a specific phase, review the generated output, approve decisions, and move the artifact into the next stage with traceability.
Portal concept
Maintain the product roadmap, sprint goals, backlog, risks, owners, decisions, and open questions.
Convert strategy, interviews, and pharma workflow knowledge into clear requirements with acceptance criteria.
Explore product flows, journey maps, information architecture, screen concepts, and operating scenarios.
Design the tenant model, RBAC, audit logging, offline sync, AI boundaries, integrations, and data architecture.
Use AI to scaffold components, services, database rules, tests, documentation, and refactors under engineering review.
Generate test cases from requirements, verify edge cases, run regression checks, and prepare UAT scripts.
Prepare release notes, deployment checklists, environment checks, rollback plans, and production readiness reviews.
Analyze user feedback, pilot metrics, adoption issues, support tickets, and improvement opportunities.
Protect privacy, compliance, security, domain correctness, and human accountability across every AI-assisted output.
Recommended next build step: use the secured portal to manage prompts, artifact templates, status fields, owners, and links to the current plan/mockup/code outputs.
Project Team Composition
The first Daloy team should be lean, but it cannot be purely technical. The product depends on pharma/SFE domain judgment, AI capability, workflow design, secure engineering, validation, and pilot execution. Each role should have clear accountability so AI-assisted development accelerates the work without blurring ownership.
For the prototype and MVP stage, some people may hold multiple roles. What matters is that every responsibility has an owner: product decisions, pharma workflow correctness, technical architecture, AI behavior, data governance, quality, deployment, and customer validation.
Owns: overall direction, RagingRiver positioning, strategic tradeoffs, partner/customer alignment, and final go/no-go decisions.
Owns: product requirements, roadmap, user journeys, backlog priority, acceptance criteria, and release readiness.
Owns: correctness of field-force workflows, targeting, call frequency, HCP rules, manager workflows, and commercial operations assumptions.
Owns: clickable prototype, screen flows, interaction design, demo narrative, usability testing, and field usability simplification.
Owns: architecture, codebase standards, API boundaries, data model, offline/sync approach, deployment, and technical feasibility.
Owns: AI use cases, recommendation logic, prompt behavior, data preparation, model boundaries, explainability, and evaluation criteria.
Owns: test strategy, regression coverage, UAT scripts, pilot acceptance criteria, and traceability between requirements and behavior.
Owns: privacy, access control, audit trail expectations, proof-of-engagement policy review, retention assumptions, and compliance claims.
Owns: pilot onboarding, training, support workflow, feedback collection, adoption metrics, and customer success reporting.
AI can help any role draft, analyze, test, summarize, or prototype. But AI should not be treated as the accountable owner. Every generated output must have a human reviewer and a named decision owner before it becomes part of the product, codebase, customer proposal, or compliance position.
Clickable Mockup
The mockup demonstrates Rep Today, Call Planning, HCP Co-pilot, Visit Report, Manager Command Center, Approvals, and Admin/Audit screens.
Immediate Next Steps